Qure.ai Partners with Teleradiology Solutions for Smarter Diagnoses
By MedImaging International staff writers
Posted on 06 Jun 2018
Healthcare artificial intelligence (AI) provider, Qure.ai (Maharashtra, India) has partnered with Teleradiology Solutions (Bangalore, India) and Telerad Tech (Bangalore, India) to enable smarter and faster diagnoses of X-ray and CT scan data, and reduce costs.Posted on 06 Jun 2018
Qure.ai's deep neural networks can understand and interpret medical images with unprecedented accuracy and enable machines to perform routine diagnostics, thus improving healthcare outcomes and costs. TRS, a global pioneer in remote radiology interpretation and telehealth, offers interpretation of all non-invasive imaging studies (CT, MRI, PET, nuclear medicine studies, digitized X-rays, ECG, angiography, etc.), and 3-D reconstructions of CT scans. Since its inception in 2002, TRS has reported scans for over five million patients and currently caters to the requirements of 150 hospitals and healthcare centers in more than 20 countries. Its RADSpa platform has been deployed in 24 countries and has processed more than 20 million studies and billions of images. T2 is a global health IT company and AI-enabled RIS-PACS provider for teleradiology, and for medical imaging centers and hospitals of all sizes, globally.
TRS' clinical expertise and T2’s RADSpa platform consolidates radiology report information from diverse sources, allowing radiologists to review these reports from anywhere and anytime. Qure.ai's chest X-ray technology will be integrated with T2's proprietary RIS PACS platform - RADSpa that is used by the company to provide teleradiology services globally. By integrating Qure.ai's algorithms that automatically generate abnormality reports from X-rays and CT scans, radiologists and hospitals using RADspa will be able to use cutting-edge algorithms to prioritize care, make smarter and faster diagnoses, and reduce costs. Qure.ai's chest X-ray solution can automatically screen for abnormal chest X-rays and tuberculosis; the company’s automated reads can significantly impact the screening protocol for tuberculosis across the world.
"At Qure.ai, we are expanding the reach of our AI algorithms to help medical professionals deliver better outcomes to their patients," said Prashant Warier, Co-Founder and CEO, Qure.ai. "TRS and Telerad Tech are pioneers in their respective domains, and we are excited about the impact this partnership will have on the millions of patients' lives they touch."
"Making sure that doctors and hospitals have the necessary and highest quality information has to be the topmost priority," said Dr Arjun Kalyanpur, CEO Teleradiology Solutions. "Diseases that are of public health importance worldwide such as tuberculosis, are within our focus of interest with a goal of providing high-quality diagnostics to facilitate early detection. Qure.ai, TRS and T2 have a shared vision when it comes to achieving this goal, and we strongly believe this will be highly beneficial for doctors, hospitals and patients alike."
Related Links:
Qure.ai
Teleradiology Solutions
Telerad Tech